Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

W D Figg

Showing results (21-30 of 135) with videos related to

Pageof 14
Sort By:
Southern Medical Journal|May 1, 1993
Ondansetron: a novel antiemetic agentW D Figg, C L Graham, L J Hak, et al.
Invasion & Metastasis|January 21, 2000
UCN-01, a protein kinase C inhibitor, inhibits endothelial cell proliferation and angiogenic hypoxic responseE A Kruger, M V Blagosklonny, S C Dixon, et al.
Clinical Pharmacokinetics|May 1, 1997
Pharmacokinetic studies with recombinant cytokines. Scientific issues and practical considerationsS C Piscitelli, W G Reiss, W D Figg, et al.
Cancer Chemotherapy and Pharmacology|June 5, 1999
Thalidomide up-regulates prostate-specific antigen secretion from LNCaP cellsS C Dixon, E A Kruger, K S Bauer, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|September 6, 2001
Alendronate does not interfere with 99mTc-methylene diphosphonate bone scanningJ A Carrasquillo, M Whatley, V Dyer, et al.
Pharmacotherapy|March 20, 2001
Phenylacetate pharmacokinetics based on iterative two-stage population analysisA H Burstein, E Reed, A C Tompkins, et al.
Journal of Molecular Medicine (Berlin, Germany)|July 30, 1999
The androgen receptor: genetic considerations in the development and treatment of prostate cancerK J Cude, S C Dixon, Y Guo, et al.
Prostate Cancer and Prostatic Diseases|December 24, 2002
Malignant ascites as only manifestation of metastatic prostate cancerM W Saif, W D Figg, S Hewitt, et al.
The Journal of Pharmacology and Experimental Therapeutics|February 13, 2001
Human CYP1B1 and anticancer agent metabolism: mechanism for tumor-specific drug inactivation?B Rochat, J M Morsman, G I Murray, et al.
The American Journal of Cardiology|November 15, 1995
Effects of the antiestrogen tamoxifen on low-density lipoprotein concentrations and oxidation in postmenopausal womenV Guetta, R M Lush, W D Figg, et al.
Pageof 14

Showing results (21-30 of 135) with videos related to

Sort By:
Pageof 14
Southern Medical Journal|May 1, 1993
Ondansetron: a novel antiemetic agentW D Figg, C L Graham, L J Hak, et al.
Invasion & Metastasis|January 21, 2000
UCN-01, a protein kinase C inhibitor, inhibits endothelial cell proliferation and angiogenic hypoxic responseE A Kruger, M V Blagosklonny, S C Dixon, et al.
Clinical Pharmacokinetics|May 1, 1997
Pharmacokinetic studies with recombinant cytokines. Scientific issues and practical considerationsS C Piscitelli, W G Reiss, W D Figg, et al.
Cancer Chemotherapy and Pharmacology|June 5, 1999
Thalidomide up-regulates prostate-specific antigen secretion from LNCaP cellsS C Dixon, E A Kruger, K S Bauer, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|September 6, 2001
Alendronate does not interfere with 99mTc-methylene diphosphonate bone scanningJ A Carrasquillo, M Whatley, V Dyer, et al.
Pharmacotherapy|March 20, 2001
Phenylacetate pharmacokinetics based on iterative two-stage population analysisA H Burstein, E Reed, A C Tompkins, et al.
Journal of Molecular Medicine (Berlin, Germany)|July 30, 1999
The androgen receptor: genetic considerations in the development and treatment of prostate cancerK J Cude, S C Dixon, Y Guo, et al.
Prostate Cancer and Prostatic Diseases|December 24, 2002
Malignant ascites as only manifestation of metastatic prostate cancerM W Saif, W D Figg, S Hewitt, et al.
The Journal of Pharmacology and Experimental Therapeutics|February 13, 2001
Human CYP1B1 and anticancer agent metabolism: mechanism for tumor-specific drug inactivation?B Rochat, J M Morsman, G I Murray, et al.
The American Journal of Cardiology|November 15, 1995
Effects of the antiestrogen tamoxifen on low-density lipoprotein concentrations and oxidation in postmenopausal womenV Guetta, R M Lush, W D Figg, et al.
Pageof 14